Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Sermorelin and ipamorelin: what is in it and does it work?

Sermorelin and ipamorelin pair a formerly approved GHRH fragment with a ghrelin mimetic. The pair is untested, and ipamorelin has no compounding basis.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

At a glance

Sermorelin and ipamorelin is a pairing of GHRH(1-29), once sold as the approved drug Geref, with the ghrelin receptor agonist ipamorelin, marketed to raise growth hormone. No study has tested the combination. Sermorelin's compounding status is unsettled and ipamorelin has no federal basis to be compounded, so neither does the blend.

Evidence: Blend never studiedRegulatory: No federal basis to compoundWADA: WADA prohibited
What is in it
Sermorelin, Ipamorelin
Evidence for the combination
No published study of the blend. Each ingredient is graded on its own.
Legal status
No federal basis to compound, set by Ipamorelin.
Tested athletes
Prohibited: Sermorelin and Ipamorelin are on the WADA list.

What is in the sermorelin and ipamorelin blend?

Sermorelin and ipamorelin contains Sermorelin and Ipamorelin. Sold as a premixed vial or as two vials, in amounts that vary by seller. Some licensed programs prescribe compounded sermorelin on its own; the ipamorelin component has no federal basis to be compounded. PeptideAgent does not name or link sellers.

Also searched as: Sermorelin ipamorelin; Sermorelin/ipamorelin blend; Sermorelin and ipamorelin blend.

Ingredients in the sermorelin and ipamorelin blend, with each peptide's own evidence grade, FDA status, and WADA status
IngredientWhy it is in the mixStatus (alone)
SermorelinSold as the GHRH component, the shortest fragment of GHRH with full activity, backed by small human trials from the 1980s and 1990s.
Evidence: Human RCT evidence
Regulatory: Former FDA approval (Geref)
WADA: WADA prohibited
IpamorelinAdded to trigger growth hormone pulses through the ghrelin receptor, based on animal studies and one small human pharmacology study.
Evidence: Human RCT evidence
Regulatory: Nomination withdrawn
WADA: WADA prohibited

Grades and statuses come from each peptide's own record and update with it. Grades follow the methodology.

Why are these peptides combined in the sermorelin and ipamorelin blend?

The pairing uses the same logic as other GHRH and ghrelin mimetic combinations: stimulate growth hormone through both release pathways. A 1990 study in 18 healthy men found that GHRH and a synthetic ghrelin receptor hexapeptide given together released more growth hormone than either alone.

Sermorelin itself was approved as Geref in 1990 for diagnosis and in 1997 for treating growth hormone deficiency in children. The sponsor discontinued it in 2008, and FDA later determined the withdrawal was not for reasons of safety or effectiveness. Its adult evidence is small: in a 5 month trial in 19 adults aged 55 to 71, nightly sermorelin raised nocturnal growth hormone and IGF-1 and increased skin thickness, with lean mass and insulin sensitivity gains in men only. [1] [2] [4] [8]

Has the sermorelin and ipamorelin blend been studied?

No published study has tested sermorelin with ipamorelin.

The 1990 synergy study used GHRH and a different ghrelin receptor peptide in single intravenous doses. It did not use ipamorelin, repeated dosing, or any outcome other than growth hormone levels over about an hour.

One small human pharmacology study showed a single IV infusion of ipamorelin releases growth hormone in healthy men; its only randomized trial (postoperative ileus) was negative; no human trial measured body composition or muscle. [1] [6] [12]

What each ingredient has shown alone

  • Sermorelin (human RCT evidence). Formerly FDA approved piece of growth hormone releasing hormone (Geref, withdrawn 2009 for business reasons); small trials show higher GH and IGF-1.
  • Ipamorelin (human RCT evidence). Growth hormone releaser acting on the hunger hormone (ghrelin) receptor; its one randomized placebo controlled trial, after bowel surgery, found no benefit.

Sermorelin and ipamorelin results and before and after claims

No study has measured muscle, fat, sleep, or recovery outcomes with the pair. The measured sermorelin results are modest: in 19 older adults, higher nocturnal growth hormone and IGF-1, thicker skin, and, in men only, more lean mass and better insulin sensitivity, with no change in sleep quality.

Sermorelin before and after claims that go beyond those findings are untested, and adding ipamorelin has no measured effect in people.

A 2026 review of growth hormone axis peptides used outside medical care describes the uncertainty created by stacking in unregulated supply and the lack of evidence for claimed body recomposition benefits. [2] [7]

What are the side effects of the sermorelin and ipamorelin blend?

Sermorelin trials reported injection site pain and redness, flushing, headache, and dizziness, transient hyperlipidemia in the adult trial, and rising fasting glucose and insulin in children. Antibodies to sermorelin were reported in the pediatric program without apparent loss of effect.

Ipamorelin adds increased appetite, flushing, and headache reported anecdotally, and FDA cited immunogenicity risk from impurities in its Category 2 evaluation. Two growth hormone stimulants together could add up glucose and fluid effects; no study has checked.

A 2026 review of growth hormone axis peptides lists fluid retention, joint and muscle pain, appetite changes, and blood glucose problems among reported adverse effects of this class, and flags unproven concerns about growth-promoting effects. [2] [4] [7] [9]

Reported for each ingredient

From each peptide's record. These were reported for the peptide alone, not for the blend. Absence of data is not evidence of safety.

Side effects reported for each ingredient of the sermorelin and ipamorelin blend
IngredientReported side effects and safety notes
Sermorelin
  • Injection site pain, redness, or swelling (most common in the pediatric trials)
  • Facial flushing, headache, and dizziness after injection
  • Transient hyperlipidemia in the adult trial, which resolved by study end
  • Rising fasting glucose and insulin during treatment in children
Ipamorelin
  • No safety signal versus placebo in the 7 day intravenous ileus trial (adverse events 87.5% versus 94.8%, mostly surgical)
  • Injection site reactions, headache, flushing, and lightheadedness reported anecdotally
  • Increased appetite (ghrelin receptor effect) reported anecdotally
  • FDA cited immunogenicity risk from aggregation and impurities and limited safety data by the routes used in compounding when it placed ipamorelin in Category 2
Regulatory: No federal basis to compoundWADA: WADA prohibited

A blend inherits the strictest status among its ingredients, because a mixed product is only as lawful as its least lawful component. For the sermorelin and ipamorelin blend that is Ipamorelin: no federal basis to compound. At least one ingredient is not FDA approved and not on the 503A bulks list, so a licensed pharmacy has no federal basis to compound the mix.

Why blends like this are sold as research chemicals

A drug for human use in the United States has to be FDA approved or lawfully compounded by a licensed pharmacy for a named patient under a prescription. This blend can be neither, so vials sold under its name carry labels such as “for research use only” or “not for human consumption”. That label does not make a product lawful to inject, and it means no one has checked the vial for identity, purity, sterility, or amount. [10]

WADA status

Sermorelin and Ipamorelin are prohibited at all times on the WADA list, so any product containing them is prohibited for athletes subject to anti-doping testing.

State rules: peptide laws by state. All FDA actions: regulatory tracker.

What does the sermorelin and ipamorelin blend cost, and what can a provider lawfully offer?

Sermorelin has no currently approved product. Many 503A pharmacies compound it on the basis of its former approval, and whether that satisfies federal law depends on how a state board and the pharmacy read it, which is why its FDA status is recorded as unsettled.

Ipamorelin has no federal basis to be compounded: its 503A nominations were withdrawn, it is not on the 503A bulks list, and it is not a component of an approved drug. A vial containing ipamorelin has no federal basis to be compounded, so the blend has no lawful price.

Licensed programs that prescribe compounded sermorelin alone publish their prices; the sermorelin cost page summarizes them. Tesamorelin, a different GHRH analog, is the only one in the catalog with current FDA approval. [8] [9] [10]

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [13] [14] [15]

Being offered does not change the legal status of the sermorelin and ipamorelin blend. Ipamorelin is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound the mix. [9] [10]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [9] [13] [16] [17] [18] [19]

What that means for you

  • A pharmacy that compounds the sermorelin and ipamorelin blend is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [13] [16]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [19]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [20]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [21] [22]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [9]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, the sermorelin and ipamorelin blend contains at least one ingredient that is prohibited under the WADA Prohibited List. [11]

If you're going ahead anyway

These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound the sermorelin and ipamorelin blend, with or without a prescription. [10]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [23] [24] [25]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [15] [25] [26]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [19] [27] [28] [29] [30] [31]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [19]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [23]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [15]
  • Pharmacy: Is this made for me on a prescription written in my name? [26]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [15] [25]
  • Prescriber: What is the legal basis for a pharmacy to compound the sermorelin and ipamorelin blend? Is it FDA approved or on the 503A bulks list? [10] [19]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [15]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [20]

Compare the ingredients

Blends that share an ingredient

  • CJC-1295 and ipamorelin: CJC-1295 and ipamorelin pair a GHRH analog with a ghrelin mimetic to raise growth hormone. The pair is untested, and neither peptide has a lawful path.
  • Tesamorelin and ipamorelin: Tesamorelin is FDA approved as Egrifta; ipamorelin has no compounding basis. Mixed together they are untested and cannot be compounded.

Frequently asked questions

What is sermorelin and ipamorelin?

It is a pairing of sermorelin, a GHRH fragment once sold as the approved drug Geref, with ipamorelin, a ghrelin receptor agonist, marketed to raise growth hormone. The pair has never been tested. [3] [4]

Does sermorelin with ipamorelin work?

It has not been studied. Sermorelin raised growth hormone and IGF-1 in small trials, ipamorelin's one randomized human trial was negative, and the synergy idea comes from single-dose studies of other molecules. [1] [2] [6]

Is sermorelin still approved?

Not today. Sermorelin was approved as Geref in 1990 and 1997, then discontinued by its sponsor; the approvals were withdrawn in 2009, and FDA later found the withdrawal was not for safety or effectiveness reasons. [4] [8]

Is sermorelin and ipamorelin legal?

The blend is not. Sermorelin alone is compounded by many pharmacies on the basis of its former approval, but ipamorelin has no federal basis to be compounded, so neither does a product containing both. [8] [10]

What are the side effects of sermorelin and ipamorelin?

The pair has no safety study. Sermorelin trials reported injection site reactions, flushing, headache, and transient lipid and glucose changes, and ipamorelin adds an unapproved ingredient FDA flagged for immunogenicity risk. [2] [4] [9]

Is sermorelin and ipamorelin banned in sport?

Yes. Both are named in WADA section S2 and are prohibited at all times. [11]

How does sermorelin and ipamorelin compare with CJC-1295 and ipamorelin?

Both pair a GHRH analog with ipamorelin, and neither pair has been tested. Sermorelin is short acting with small trials and a former approval; CJC-1295 with DAC is long acting with small hormone trials and no approval. [2] [5]

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Bowers CY et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990PubMed 2108187, 1990
  2. [2]Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997PubMed 9141536, 1997
  3. [3]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998PubMed 9849822, 1998
  4. [4]Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999PubMed 18031173, 1999
  5. [5]Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006PubMed 16352683, 2006
  6. [6]Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014PubMed 25331030, 2014
  7. [7]Dominikowski A et al. The emerging landscape of performance-enhancing peptides modulating the GH-IGF-1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026PubMed 42395176, 2026
  8. [8]Federal Register, March 4, 2013: Determination that Geref (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness (NDA 19-863 and NDA 20-443)Federal Register, 2013
  9. [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
  10. [10]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 30). Sermorelin and ipamorelin: what is in it and does it work?. https://peptideagent.ai/blends/sermorelin-ipamorelin
HTML link
<a href="https://peptideagent.ai/blends/sermorelin-ipamorelin">Sermorelin and ipamorelin: what is in it and does it work?</a>, PeptideAgent, updated September 30, 2026.